There is no solid evidence for or against recommending convalescent plasma to treat patients hospitalized with COVID-19, a government panel said Tuesday, less than 10 days after the Food and Drug ...
Blood tests in development for Alzheimer’s disease rely on Aβ and phosphorylated tau, markers of its hallmark pathologies. While powerful, these markers are only accurate in about 90 percent of cases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results